WELL Enterprise Value Over E B I T D A from 2010 to 2025

WELL Stock  CAD 5.93  0.29  4.66%   
WELL Health Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to grow to 15.33 this year. During the period from 2010 to 2025, WELL Health Enterprise Value Over EBITDA quarterly data regression pattern had sample variance of  262,645 and median of (5.12). View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
14.6
Current Value
15.33
Quarterly Volatility
512.48905933
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check WELL Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among WELL Health's main balance sheet or income statement drivers, such as Interest Expense of 37.8 M, Selling General Administrative of 256.8 M or Other Operating Expenses of 887.4 M, as well as many indicators such as Price To Sales Ratio of 1.28, Dividend Yield of 0.0 or PTB Ratio of 1.23. WELL financial statements analysis is a perfect complement when working with WELL Health Valuation or Volatility modules.
  
This module can also supplement various WELL Health Technical models . Check out the analysis of WELL Health Correlation against competitors.

Other Information on Investing in WELL Stock

WELL Health financial ratios help investors to determine whether WELL Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WELL with respect to the benefits of owning WELL Health security.